(VIANEWS) – NVIDIA (NVDA), Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (OMAB), Interactive Brokers Group (IBKR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
224.9% sales growth and 69.17% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $7.6.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 77.14. Meaning, the purchaser of the share is investing $77.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 69.17%.
Moving Average
NVIDIA’s value is way above its 50-day moving average of $494.82 and way above its 200-day moving average of $423.19.
Revenue Growth
Year-on-year quarterly revenue growth grew by 205.5%, now sitting on 44.87B for the twelve trailing months.
Yearly Top and Bottom Value
NVIDIA’s stock is valued at $586.29 at 00:22 EST, below its 52-week high of $595.00 and way above its 52-week low of $178.18.
Previous days news about NVIDIA(NVDA)
- According to Zacks on Friday, 19 January, "Additionally, the blockbuster earnings results of the last reported quarter of NVIDIA - the largest global manufacturer of generative AI chipsets - raised expectations of investors that the market for AI will show strong growth in the coming decade.", "Zacks Rank #1 NVIDIA has an expected revenue and earnings growth rate of 53.7% and 63.1%, respectively, for the current year (ending January 2025). "
- According to Zacks on Friday, 19 January, "Some better-ranked stocks in the broader technology sector are Arista Networks (ANET Quick QuoteANET – Free Report) , NVIDIA (NVDA Quick QuoteNVDA – Free Report) and Itron (ITRI Quick QuoteITRI – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. "
- According to Zacks on Friday, 19 January, "The Earnings ESP for NVIDIA Corporation (NVDA Quick QuoteNVDA – Free Report) is +3.68% and it sports a Zacks Rank of 1. "
2. Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (OMAB)
14.9% sales growth and 61.31% return on equity
Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., together with its subsidiaries, holds concessions to develop, operate, and maintain airports in Mexico. The company operates 13 international airports in Monterrey, Acapulco, Mazatlán, Zihuatanejo, Ciudad Juárez, Reynosa, Chihuahua, Culiacán, Durango, San Luis Potosí, Tampico, Torreón, and Zacatecas cities. It also operates the NH Collection Hotel in Terminal 2 of the Mexico City International Airport; and a hotel under the Hilton Garden Inn name at the Monterrey International Airport. In addition, the company provides aeronautical services, which include passenger, aircraft landing and parking, boarding and unloading, passenger walkway, and airport security services. Further, it offers complementary services that comprise leasing of space to airlines, cargo handling, baggage-screening, permanent and non-permanent ground transportation, and access rights services; non-aeronautical services, such as leasing of space at its airports to retailers, restaurants, and other commercial tenants, as well as maintaining of parking facilities and advertising; and diversification services, which consists of operation and lease of the industrial park and real estate services, as well as hotel and air cargo logistics services. Additionally, the company provides construction services. It has a strategic alliance with VYNMSA Desarrollo Inmobiliario, S.A. de C.V. to build and operate an industrial park at the Monterrey airport. The company was founded in 1998 and is headquartered in Mexico City, Mexico.
Earnings Per Share
As for profitability, Grupo Aeroportuario del Centro Norte S.A.B. de C.V. has a trailing twelve months EPS of $5.18.
PE Ratio
Grupo Aeroportuario del Centro Norte S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 14.6. Meaning, the purchaser of the share is investing $14.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.31%.
Moving Average
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.’s worth is above its 50-day moving average of $73.18 and below its 200-day moving average of $82.35.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 17, 2023, the estimated forward annual dividend rate is 4.39 and the estimated forward annual dividend yield is 5.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 14.41B for the twelve trailing months.
3. Interactive Brokers Group (IBKR)
9.5% sales growth and 21.9% return on equity
Interactive Brokers Group, Inc. operates as an automated electronic broker worldwide. The company specializes in routing, executing, and processing trades in stocks, options, futures, foreign exchange instruments, bonds, mutual funds, exchange traded funds (ETFs), metals, and cryptocurrencies. It also custodies and services accounts for hedge and mutual funds, ETFs, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. In addition, it offers custody, prime brokerage, securities, and margin lending services. The company serves institutional and individual customers through approximately 150 electronic exchanges and market centers. Interactive Brokers Group, Inc. was founded in 1977 and is headquartered in Greenwich, Connecticut.
Earnings Per Share
As for profitability, Interactive Brokers Group has a trailing twelve months EPS of $2.84.
PE Ratio
Interactive Brokers Group has a trailing twelve months price to earnings ratio of 31.4. Meaning, the purchaser of the share is investing $31.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.9%.
4. Regeneron Pharmaceuticals (REGN)
8.3% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.06.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.67. Meaning, the purchaser of the share is investing $26.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
